Response to imatinib mesylate in patients with hypereosinophilic syndrome

International Journal of Hematology

Volumn 96, Issue 3, 2012, Pages 320-326

  Arefi, Maryam ^a   García, Juan L ^b,c   Briz, M Montserrat ^d   De Arriba, Felipe ^e   Rodríguez, Juan N ^f   Martín Núñez, Guillermo ^g   Martý́nez, Joaquín ^h   López, Javier ⁱ   Suárez, Julio G ^j   Moreno, M José ^k   Merino, M Ángeles ^l   Gutiérrez, Norma C ^c,m   Hernández Rivas, Jesús Maria ^m,n  

^a HOSPITAL CLÍNICO UNIVERSITARIO DE VALLADOLID   (Spain)

^b Instituto de Estudios de Ciencias de La Salud de Castilla y Leon   (Spain)

^c Centro de Investigacion del Cancer   (Spain)

^d HOSPITAL SIERRALLANA   (Spain)

^e HOSPITAL MORALES MESEGUER   (Spain)

^f HOSPITAL JUAN RAMÓN JIMÉNEZ   (Spain)

^g HOSPITAL VIRGEN DEL PUERTO   (Spain)

^h HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

ⁱ HOSPITAL RAMÓN Y CAJAL   (Spain)

^j HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

^k HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^l HOSPITAL COSTA DEL SOL   (Spain)

^m HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

ⁿ UNIVERSITY OF SALAMANCA   (Spain)

more..

Author keywords

Chronic eosinophilic leukemia; Cytogenetic; FIP1L1 PDGFRA fusion; Fluorescent in situ hybridization (FISH); Hypereosinophilic syndrome; Imatinib

Indexed keywords

FIP1L1 PROTEIN; IMATINIB; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ANEMIA; ARTICLE; CYTOGENETICS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE FUSION; HUMAN; HYPEREOSINOPHILIC SYNDROME; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; REMISSION; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CHROMOSOME ABERRATIONS; FEMALE; HUMANS; HYPEREOSINOPHILIC SYNDROME; KARYOTYPE; MALE; MIDDLE AGED; MRNA CLEAVAGE AND POLYADENYLATION FACTORS; ONCOGENE PROTEINS, FUSION; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84867018130     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-012-1141-7     Document Type: Article

References (29)

1. Tefferi A, Gotlib J, Pardanani A. Hypereosinophilic syndrome and clonal eosinophilia: point-of-care diagnostic algorithm and treatment update. Mayo Clin Proc. 2010;85:158-64.
2. Bain BJ, Gilliland DG, Horny HP, Vardiman JW. Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB or FGFR1. In: World Health classification of tumors: pathology and genetics of tumors of haematopoietic and lymphoid tissues, 4th ed. Lyon: IARC Press; 2007. pp 68-73.
3. Bain BJ, Flethcher SH. Chronic eosinophilic leukemias and the myeloproliferative variant of the hypereosinophilic syndrome. Immunol Allergy Clin North Am. 2007;27:377-88.
4. Pardanani A, Tefferi A. Primary eosinophilic disorders: a concise review. Curr hematol Malig Rep. 2008;3:37-43.
5. Hernández JM, Cañizo MC, Cuneo A, García JL, Gutiérrez NC, González M, et al. Clinical, hematological and cytogenetic characteristics of atypical chronic myeloid leukemia. Ann Oncol. 2000;11:441-4.
6. Gotlib J, Cools J, Malone JM 3rd, Schrier SL, Gilliland DG, Coutre SE. The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management. Blood. 2004;103:2879-91.
7. Roufosse FE, Goldman M, Cogan E. Hypereosinophilic syndromes. Orphanet J Rare Dis. 2007;11:2-37.
8. Goldman JM, Melo JV. Chronic myeloid leukaemia-advances in biology and new approaches to treatment. N Engl J Med. 2003;349:1451-64.
9. Cools J, Stover EH, Wlodarska I, Marynen P, Gilliland DG. The FIP1L1-PDGFRalpha kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia. Curr Opin Hematol. 2004;11:51-7.
10. Pardanani A, Ketterling RP, Li CY, Patnaik MM, Wolanskyj AP, Elliott MA, et al. FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature. Leuk Res. 2006;30:965-70.
11. Helbig G, Stella-Ho?owiecka B, Majewski M, Ca?becka M, Gajkowska J, Klimkiewicz R, et al. A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in FIP1L1-PDGFRA- expressing patients. Br J Haematol. 2008;141:200-4.
12. Intermesoli T, Delaini F, Acerboni S, Salmoiraghi S, Spinelli O, Guerini V, et al. A short low-dose imatinib trial allows rapid identification of responsive patients in hypereosinophilic syndromes. Br J Haematol. 2009;147:681-5.
13. Brothman AR, Persons DL, Shaffer LG. Nomenclature evolution: changes in the ISCN from the 2005 to the 2009 edition. Cytogenet Genome Res. 2009;127:1-4.
14. Gonzalez MB, Hernandez JM, Garcia JL, Lumbreras E, Castellanos M, Fernandez-Calvo J, et al. The value of fluorescence in situ hybridization for the detection of 11q in multiple myeloma. Haematologica. 2004;89:1213-8.
15. Gotlib J, Berubé C, Growney JD, Chen CC, George TI, Williams C, et al. Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816 V KIT mutation. Blood. 2005;106:2865-70.
16. Bain BJ. Relationship between idiopathic hypereosinophilic syndrome, eosinophilic leukemia and systemic mastocytosis. Am J Hematol. 2004;77:82-5.
17. Pardanani A, Brockman SR, Paternoster SF, Flynn HC, Ketterling RP, Lasho TL, et al. FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood. 2004;104:3038-45.
18. Gleich GJ, Leiferman KM. The hypereosinophilic syndromes: current concepts and treatments. Br J Haematol. 2009;145: 271-85.
19. Klion AD, Robyn J, Akin C, Noel P, Brown M, Law M, et al. Molecular remission and reversal of myelofibrosis in response to Imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. Blood. 2004;103: 473-8.
20. Ascione L, De Michele M, Accadia M, Spadaro P, Rumolo S, Tuccillo B. Reversal of cardiac abnormalities in a young man with idiopathic hypereosinophilic sndromeusing a tyrosine kinase inhibitor. Eur J Echocardiogr. 2004;5:386-90.
21. Muller AM, Martens UM, Hofmann SC. Bruckner-Tuderman L, Mertelsmann R, Lubbert M. Imatinib mesylate as a novel treatment option for hypereosinophilic syndrome: two case reports and a comprehensive review of the literature. Ann Hematol. 2006;85:1-16.
22. Pardanani A, Tefferi A. Imatinib targets other than bcr/abl and their clinical relevance in myeloid disorders. Blood. 2004;104:1931-9.
23. Jovanovic JV, Score J, Waghorn K, Cilloni D, Gottardi E, Metzgeroth G, et al. Low-dose Imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. Blood. 2007;109:4635-40.
24. Wolf D, Gastl G, Rumpold H. Complete remission of an idiopathic hypereosinophilic syndrome while using Imatinib. Dtsch Med Wochenschr. 2004;129:2104-6.
25. Butterfield JH. Success of short-term, higher-dose imatinib mesylate to induce clinical response in FIP1L1-PDGFRalpha-negative hypereosinophilic syndrome. Leuk Res. 2009;33:1127-9.
26. Stover EH, Chen J, Folens C, Lee BH, Mentens N, Marynen P, et al. Activation of FIP1L1-PDGFR alpha requires disruption of the juxtamembrane domain of PDGFRalpha and is FIP1L1- independent. Proc NatI Acad Sci USA. 2006;103:8078-83.
27. Lierman E, Michaux L, Beullens E, Pierre P, Marynen P, Cools J, et al. FIP1L1-PDGFRalpha D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRalpha T674I eosinophilic leukemia with single agent sorafenib. Leukemia. 2009; 23:845-51.
28. Halaburda K, Prejzner W, Szatkowski D, Limon J, Hellmann A. Allogeneic bone marrow transplantation for hypereosinophilic syndrome: long-term follow-up with eradication of FIP1L1- PDGFRA fusion transcript. Bone Marrow Transplant. 2006;38: 319-20.
29. Ueno NT, Anagnostopoulos A, Rondón G, Champlin RE, Mikhailova N, Pankratova OS, et al. Successful non-myeloablative allogeneic transplantation for treatment of idiopathic hypereosinophilic syndrome. Br J Haematol. 2002;119:131-4.